NDRC Investigation Leads To Price Cuts For Infant Formulas; Could Drugs Be Next?
This article was originally published in PharmAsia News
Executive Summary
Global firms cut prices for infant formula following China’s investigation into possible antitrust law violations, and the potential impact on pharma is playing out ahead of a new government price survey.